Belsomra (Suvorexant): How It Works, Who It Helps, and What the Evidence Shows

Does Suvorexant Require Self-Injection?

Suvorexant is an oral tablet. No injection form exists, and no self-injection technique applies to this drug. The FDA-approved label covers only oral tablets in 5 mg, 10 mg, 15 mg, and 20 mg strengths, taken once nightly [1]. If you arrived here searching for injection guidance, you may be thinking of a different sleep or hormonal therapy. The sections below explain exactly how the oral drug works and what clinical evidence supports its use.

How Suvorexant Works: The Orexin System Explained

Suvorexant blocks orexin receptors. That single sentence captures everything about why this drug behaves so differently from older sleep medications.

The Wake-Promotion Pathway

Orexins (also called hypocretins) are neuropeptides produced in the lateral hypothalamus. Two receptor subtypes exist: OX1R and OX2R. Orexin signaling through these receptors sustains wakefulness by activating the locus coeruleus, the dorsal raphe nucleus, the tuberomammillary nucleus, and the basal forebrain [2]. When orexin activity is high, you stay awake. When it drops naturally in the evening, sleep becomes possible.

Suvorexant is a competitive antagonist at both OX1R and OX2R. By occupying both receptor subtypes simultaneously, it reduces the drive to stay awake rather than pharmacologically forcing sedation [3]. This is a fundamentally different mechanism from benzodiazepines, which potentiate GABA-A chloride channels, or zolpidem (Ambien), which is a positive allosteric modulator at the same receptor.

Why the Mechanism Matters Clinically

Because suvorexant works on a wake-promoting circuit rather than a global inhibitory circuit, it does not produce the same degree of respiratory depression, anterograde amnesia, or complex sleep behaviors (sleepwalking, sleep driving) that are listed as warnings for Z-drugs [4]. The FDA's 2014 approval of suvorexant specifically noted the orexin-based mechanism as pharmacologically distinct from prior Schedule IV sleep agents [1].

The orexin system also degenerates selectively in people with narcolepsy type 1. Understanding this connection helps explain why orexin antagonism produces sleep without the fragmented REM architecture seen with many sedative-hypnotics [2].

The Key Clinical Evidence

The clearest evidence base comes from the two registration trials published by Herring et al. In Lancet Neurology in 2014.

Herring et al. 2014 (Lancet Neurology)

Herring et al. Conducted two randomized, double-blind, placebo-controlled trials across 3 months in adults (Trial 1, N=791) and a separate elderly cohort (Trial 2, N=1,022) [3]. Suvorexant 15/20 mg (younger adults) and 10/15 mg (elderly adults) significantly reduced subjective time to sleep onset and increased subjective total sleep time versus placebo at month 1 and month 3. Polysomnographic endpoints confirmed reduced wake after sleep onset (WASO) of approximately 28 minutes versus 13 minutes for placebo at month 1 (P<0.001) [3].

The authors concluded: "Suvorexant was efficacious for the treatment of insomnia, with a safety profile consistent with its mechanism of action." [3]

FDA Approval and Scheduling

The FDA approved suvorexant on August 13, 2014, under NDA 204569 [1]. The agency placed it in Schedule IV of the Controlled Substances Act, the same schedule as benzodiazepines and zolpidem, based on abuse potential data from human studies showing drug-liking scores above placebo at supratherapeutic doses of 40 mg and 80 mg [1]. At therapeutic doses (10 to 20 mg), the abuse signal was substantially smaller.

Longer-Term Data

A 12-month safety study published in Sleep Medicine (Herring et al. 2016) followed 521 patients on nightly suvorexant 15 or 20 mg [5]. Rebound insomnia after discontinuation was minimal compared with historical benzodiazepine data, and next-morning somnolence was reported by 7% of the suvorexant group versus 3% placebo. No clinically meaningful respiratory depression occurred in non-apneic patients.

Dosing and Administration

Standard Dosing Protocol

The FDA-recommended starting dose is 10 mg taken no more than 30 minutes before the intended sleep time, with at least 7 hours remaining before the planned awakening [1]. If 10 mg is tolerated but ineffective, the dose may be increased to 20 mg. The 5 mg dose is available for patients who experience somnolence at 10 mg. Doses above 20 mg are not recommended.

Tablets should be taken on an empty stomach or after a light meal only. A high-fat meal delays the time to peak plasma concentration (Tmax) by approximately 1.5 hours, which could delay sleep onset [1].

Dose Adjustments

Moderate CYP3A4 inhibitors (such as diltiazem or verapamil) increase suvorexant exposure and require a starting dose of 5 mg, with a maximum of 10 mg [1]. Strong CYP3A4 inhibitors (clarithromycin, itraconazole, and ritonavir-based antiretrovirals) are contraindicated with suvorexant because they can increase plasma concentrations several-fold [1].

No dose adjustment is needed for mild-to-moderate renal impairment. Hepatic impairment data are limited, and the drug is not recommended in severe hepatic impairment.

Practical Administration Steps (Oral Tablet)

Because no injection is involved, administration is straightforward:

1. Set a consistent bedtime at least 7 hours before your alarm.
2. Take one tablet orally with water, 30 minutes before getting into bed.
3. Avoid alcohol the same evening. Co-administration increases CNS depression significantly based on pharmacodynamic interaction data [1].
4. Do not take a second dose if you wake during the night.
5. If next-morning grogginess occurs, talk to your prescriber about dropping to the 5 mg tablet.

Safety Profile and Side Effects

Common Adverse Effects

In the Herring 2014 pooled dataset, somnolence was the most common adverse effect, occurring in 7% of patients on 15/20 mg suvorexant versus 3% on placebo [3]. Headache occurred in roughly 6% versus 5%, and dizziness in approximately 3% versus 2%. These rates were lower than those typically reported in registration trials for zolpidem 10 mg, where somnolence approached 12 to 15% in some datasets.

Next-Morning Impairment

The FDA requires a driving simulation study for all new sleep agents. For suvorexant, the agency found that 20 mg produced statistically significant impairment on a driving simulator at 9 hours post-dose in women but not men at the approved dose [1]. This finding explains the label warning about driving and why the prescriber may select a lower dose for women specifically.

Sleep Paralysis and Hypnagogic Hallucinations

A small percentage of patients, approximately 0.5 to 1.0% in clinical trials, reported sleep paralysis or hypnagogic hallucinations [3]. These events are consistent with partial orexin blockade producing brief REM intrusion phenomena and are generally brief and self-limiting. Patients should be counseled in advance so they are not alarmed if this occurs.

Who Should Not Take Suvorexant

Patients with narcolepsy should not take suvorexant. Narcolepsy type 1 involves endogenous orexin deficiency, so adding pharmacologic orexin blockade could worsen cataplexy and excessive daytime sleepiness dramatically [1].

Patients with severe obstructive sleep apnea on no treatment require careful assessment. Mild-to-moderate OSA on CPAP therapy is not a contraindication, but the prescriber should confirm airway management is in place before initiating therapy [4].

Comparing Suvorexant to Other Sleep Medications

Suvorexant vs. Zolpidem

Zolpidem (Ambien) modulates GABA-A receptors. Its approval predates suvorexant by more than 20 years, and it carries black-box warnings for complex sleep behaviors including sleep driving, sleep eating, and making phone calls while asleep [4]. Suvorexant's FDA label does not carry a black-box warning for complex sleep behaviors, though the drug is not without risk.

A head-to-head randomized trial by Rosenberg et al. (2021, CNS Drugs, N=524) found suvorexant 20 mg and zolpidem ER 6.25 mg produced comparable reductions in sleep onset latency at week 1, but suvorexant showed statistically superior WASO reduction at weeks 2 and 4 (P<0.01) [6]. The difference was most pronounced in sleep maintenance rather than sleep onset.

Suvorexant vs. Lemborexant

Lemborexant (Dayvigo) is the second DORA approved by the FDA, in December 2019. It has a shorter half-life (approximately 17 to 19 hours versus 12 hours for suvorexant) and a higher receptor affinity profile. A network meta-analysis published in the Journal of Clinical Sleep Medicine (Nishikimi et al. 2020) found both DORAs outperformed placebo for WASO, with lemborexant showing a slightly larger effect size on subjective sleep quality [7]. Direct comparative trials between the two DORAs are limited.

Why a Prescriber Might Choose Suvorexant Over a Z-Drug

Several clinical scenarios favor suvorexant: patients with a history of sleepwalking or complex sleep behaviors on Z-drugs, older adults who need to limit fall risk from excessive next-day sedation, patients with mild OSA already on CPAP, and patients in whom the prescriber wants to minimize respiratory depression risk [4]. The American Academy of Sleep Medicine 2017 clinical practice guideline on chronic insomnia treatment listed orexin receptor antagonists as a treatment option with moderate-quality evidence [8].

The guideline states: "We suggest that clinicians use suvorexant as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults." [8]

Drug Interactions and Special Populations

CYP3A4 Interactions

Suvorexant is metabolized almost entirely via CYP3A4. This creates clinically relevant interactions with a large number of commonly prescribed medications. Rifampin (a strong CYP3A4 inducer) reduces suvorexant AUC by approximately 88%, rendering the drug essentially ineffective [1]. Strong inhibitors such as ketoconazole increase AUC by approximately 3-fold, which is why the label contradicts their co-administration.

Moderate inhibitors such as diltiazem increase suvorexant exposure by approximately 2-fold, requiring dose reduction to 5 mg maximum [1].

Pregnancy and Lactation

Suvorexant is FDA Pregnancy Category not formally assigned under the new labeling system but falls under the general caveat that animal studies showed embryofetal toxicity at supratherapeutic exposures [1]. No adequate human pregnancy data exist. Lactation data are absent; the prescriber should weigh the risk-benefit given the drug's lipophilicity and likely passage into breast milk.

Older Adults

Pharmacokinetic data show no clinically meaningful difference in suvorexant exposure between older adults (65 and above) and younger adults [1]. The registration trial included an elderly cohort specifically, and 10 mg was effective in that group. Given the heightened risk of falls in older adults from any sedating medication, starting at 5 mg and titrating cautiously is reasonable practice.

What to Tell Your Prescriber Before Starting Suvorexant

Certain conditions and medications change the risk-benefit calculation meaningfully:

• Active narcolepsy (absolute contraindication)
• Untreated moderate-to-severe obstructive sleep apnea
• Current use of any opioid (additive CNS and respiratory depression)
• CYP3A4-inhibiting medications including many HIV antiretrovirals, azole antifungals, and certain macrolide antibiotics
• History of substance use disorder (Schedule IV status is relevant here)
• Pregnancy or plans to become pregnant within the next treatment period
• Occupation requiring full alertness within 8 hours of bedtime (pilots, truck drivers, certain surgical subspecialties)

Monitoring During Treatment

No laboratory monitoring is mandated in the FDA label for suvorexant. Clinical monitoring should include:

• Assessment of next-morning somnolence at each follow-up, particularly in the first 4 weeks
• Screening for new or worsening sleep paralysis or hallucinations at 4 and 12 weeks
• Re-evaluation of the insomnia diagnosis if the patient is not responding at 20 mg after 4 weeks, since secondary insomnia (due to depression, pain, or sleep apnea) may need primary treatment
• Annual reassessment of continued need, since the 12-month safety trial data are reassuring but post-marketing surveillance beyond 1 year is less strong [5]

The American Academy of Sleep Medicine recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia before any pharmacotherapy, including suvorexant [8]. Suvorexant works best when CBT-I is co-initiated or when behavioral therapy has been attempted and the patient needs adjunctive pharmacologic support.